On May 14, 2021 Mission Therapeutics ("Mission"), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), reported that management team members will be attending and presenting at Bio€quity Europe (17-19 May) (Press release, Mission Therapeutics, MAY 14, 2021, View Source [SID1234579981]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Anker Lundemose, CEO, David Luther, CFO, and Paul Wallace, CBO, will attend the digital event and will be available for partnering meetings. Mission’s corporate presentation is available to all delegates via the partneringONE digital event platform.

In addition, Anker will present on 19 May at 10:00 CET as part of the 10th CEO Workshop: Hiring and Team Building in the Age of COVID. The workshop will explore how best practices for hiring A-list talent have evolved during the pandemic, including what is expected to be the long-term impact. The panel will also discuss how they have kept their teams motivated and productive over the past year.

Bio€quity Europe Digital is an international networking platform that enables financial dealmakers and biopharma executives to meet rising biotechs. Industry leaders will debate the big questions framing the future of biopharma innovation and identify where Europe will continue to be a global leader. The three-day virtual event will include strategic panels focused on ‘Europe’s Next Act’ and will support one-to-one virtual meetings, with over 130 corporate presentations available from European and Asian biotechs.